Description: Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Home Page: kodiak.com
KOD Technical Analysis
1200 Page Mill Road
Palo Alto,
CA
94304
United States
Phone:
650 281 0850
Officers
| Name | Title |
|---|---|
| Dr. Victor Perlroth M.D. | Co-Founder, Chairman, CEO & Pres |
| Mr. John A. Borgeson CPA, M.B.A., MBA, CPA | Sr. VP, CFO & Sec. |
| Dr. Jason S. Ehrlich M.D., Ph.D. | Chief Medical Officer & Chief Devel. Officer |
| Dr. Michael S. Louie Ph.D. | Sr. VP of Digital Transformation & Chief Information Officer |
| Dr. Hong Liang | Sr. VP of Discovery Medicine |
| Ms. Almas Qudrat M.Sc. | Sr. VP of Quality Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7952 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-10-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 105 |